By analogy with semaglutide (where the STEP-4 withdrawal trial demonstrated substantial weight regain within 12 months of discontinuation), researchers should anticipate that weight regain is likely following cessation of any GLP-1 class compound, including retatrutide
Finerenone significantly reduced the incidence of the primary and secondary kidney outcomes by 18% and 24% respectively, with a number needed to treat of 29 patients for the primary outcome
A Chinese consulting firm, chyxx.com, predicts that the number of overweight and obese people in China will exceed 265 million by 2025
This step is crucial in ensuring access to necessary treatments like Wegovy or Zepbound without uncertainty over financial coverage
Patients should ask what symptoms need evaluation first, what labs may help, whether peptide therapy is appropriate, what benefits are realistic, what risks are unknown, and how progress would be monitored